Skip to content
DataLookout
Menu

NCT07489352

N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure

StatusEnrolling by Invitation
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 6 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Mar 5, 2027 to Sep 5, 2027
    • Study completion pushed from Mar 5, 2027 to Oct 5, 2027
  2. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 94 words
    • Secondary endpoint revised
    • Site details revised
  3. Notable Enrolling by invitation only
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 5, 2026 to Jul 31, 2026
    v3
  4. Notable Start date: May 5, 2026 to Sep 5, 2026v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Beta-blocker dose at 4 months post-randomization
Timeframe: 120 days

Secondary (1)

Proportion of participants taking ≥50% of target dose

Arms and interventions

N-of-1 TrialsExperimental

N-of-1 trials using a crossover withdrawal/reversal design will allow for 1-5 three-week periods as needed to identify the highest tolerated beta-blocker dose

Enhanced usual careActive comparator

We will compare the intervention to an "enhanced usual care." Our study team will not provide guidance for dose titration (this will be at physician and patient discretion); and participants will not have access to PROs or the data visualization tool. Since attention can affect outcomes, we will "enhance usual care" by conducting phone calls at the same frequency as the intervention group.

Behavioral: N-of-1 trials, Enhanced usual care

Sites

1 site in 1 country

  • New York Presbyterian Hospital/Weill Medical College of Cornell UniversityNew York, New York, United States